0001104659-26-036494
SEC filingMeiraGTx delivered strong revenue growth in 2025, driven by collaboration and licensing activities, while continuing to invest heavily in gene therapy development. Despite the net loss, improved operating cash flow signals greater efficiency in capital use.
MeiraGTx reported revenue of $81.4 million for FY2025, a 144.6% increase from $33.3 million in FY2024. This substantial growth reflects increased activity under collaboration and licensing agreements, though specific deal terms are not disclosed. The company continues to operate at a loss, with an operating income of -$106.0 million, representing a 35.5% improvement from the prior year’s -$164.2 million. The narrowing loss is attributed to lower interest expenses—driven by reduced rates on debt financing—and more efficient manufacturing cycles in certain programs.
While overall costs remain high due to continued investment in gene therapy development, cost shifts across programs highlight strategic prioritization. Increases in clinical spending were primarily linked to higher volumes of manufactured clinical trial material for ocular disease programs and AAV-GAD, alongside new preclinical studies in gene regulation. These were partially offset by reduced activity in the AAV-hAQP1 program, where fewer batches of clinical material were produced compared to the prior year. The company emphasizes that such fluctuations reflect stage-specific development needs rather than broad changes in R&D strategy.
Net cash used in operating activities improved significantly, decreasing to -$46.4 million in FY2025 from -$104.5 million in FY2024. This reflects better management of working capital and timing of payments, even as research activities expanded. Capital expenditures declined to $3.8 million from $5.0 million, suggesting focused investment in internal manufacturing capacity. Free cash flow, calculated as operating cash flow less capital expenditures, stood at -$50.2 million, indicating progress in reducing cash burn.
Management reaffirms that current facilities can support clinical, preclinical, and third-party supply obligations through regulatory approval and into commercial production, if approved. However, given sustained losses and expected future expenses, the company will require additional capital. It plans to pursue funding through equity or debt financings, collaborations, or licensing deals. No dividends are anticipated, consistent with its reinvestment-focused strategy.